厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年慢性心力衰竭的临床疗效分析

摘要

Objective To investigate the clinical efficacy of early combination of Irbesartan Hydrochlorothiazide and metoprolol in the treatment of senile chronic heart failure .Methods From January 2013 to January 2015, the ninety cases of elderly patients with chronic heart failure hospitalized in our hospital were randomly divided into two groups and the control group , 45 cases in each group .Where in the control group ,β-receptor blockers metoprolol was used for therapy , the observation group using irbesartan hydrochlorothiazide combination with metoprolol for treatment .After treatment, the efficacy of patients was observed .Results After treatment, the BNP of patients in the observation group was (83.14 ±6.32) pg/ml, LEVF was (55.32 ±3. 05)%, the BNP of control group was (101.47 ±10.08) pg/ml, LEVF was (42.72 ±3.43)%, the differences between the two groups were statistically significant (P<0.05).After treatment, 44 cases of patients in the observation group got remarkable effect , accounting for 91.67%; three cases obtained effective efficacy , accounting for 6.25%;invalid in one patient, accounting for 2.08%.After treatment, 37 cases of patients in the control group got marked effect , accounting for 77.08%;effective in 4 patients, accounting for 77.08%;invalid in 7 patients, accounting for 14.58%.The difference was statistically significant (P<0.05).Conclusions Early combination of Irbesartan Hydrochlorothiazide and metoprolol in treatment of elderly chronic heart failure patients can reduce BNP and improve LVEF , significantly improve symptoms of heart failure patients and havebetter clinical efficacy .%目的：探讨厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年性慢性心力衰竭的临床疗效。方法2013年1月至2015年1月，我院治疗老年性慢性心力衰竭患者90例，随机分为观察组和对照组，每组45例。其中对照组采用β－受体阻滞剂美托洛尔药物治疗，观察组采用厄贝沙坦氢氯噻嗪联合美托洛尔治疗。治疗后观察两组患者治疗疗效。结果治疗后观察组患者BNP 为（83．14±6．32） pg／ml， LEVF为（55．32±3．05）％，对照组患者BNP为（101．47±10．08）pg／ml，LEVF为（42．72±3．43）％，比较差异均有统计学意义（P＜0．05）。观察组治疗后显效患者44例，占91．67％；有效患者3例，占6．25％；无效患者1例，占2．08％。对照组治疗后显效患者37例，占77．08％；有效患者4例，占77．08％；无效患者7例，占14．58％。比较差异有统计学意义（ P＜0．05）。结论厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年性慢性心力衰竭，可以降低患者BNP，提高左室射血分数，明显改善患者心力衰竭症状，具有较好的临床疗效。